In conclusion, our study provides significant preclinical evidence that targeting the CDK4/6-DUB3 axis is an effective therapeutic strategy to destabilize YAP1 and suppress HCC progression. This evidence concerns the gene USP17L2 and hepatocellular carcinoma.